SCHEMBL10159110

SCHEMBL10159110

CC(C)OCCN1C(=O)CC(=O)N(CCc2ccc(F)cc2)C1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.51
MAPT P10636 5/20 0.51
MEN1 O00255 5/20 0.51
GAA P10253 3/20 0.51
HSD17B10 Q99714 2/20 0.51
USP2 O75604 2/20 0.51
HTT P42858 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ALDH1A1 P00352 6/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51
PKM P14618 1/20 0.51
SLC6A4 P31645 3/20 0.40
SLC6A3 Q01959 3/20 0.40
SLC6A2 P23975 2/20 0.40
LMNA P02545 2/20 0.39
HPGD P15428 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
BLM P54132 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10159099 0.85 MAPT (0.69) KMT2AMAPTMEN1GAAHSD17B10
SCHEMBL10159565 0.82 HSD17B10 (0.41) KMT2AMAPTMEN1GAAHSD17B10
SCHEMBL10159144 0.79 MAPT (0.61) KMT2AMAPTMEN1GAAHSD17B10
SCHEMBL10159149 0.75 MAPT (0.55) KMT2AMAPTMEN1GAAHSD17B10
SCHEMBL10159081 0.74 MAPT (0.70) KMT2AMAPTMEN1GAAHSD17B10
SCHEMBL10159189 0.74 MAPT (0.54) KMT2AMAPTMEN1GAAHSD17B10
SCHEMBL10159125 0.73 KMT2A (0.52) KMT2AMAPTMEN1GAAHSD17B10
SCHEMBL19120785 0.72 KMT2A (0.50) KMT2AMAPTMEN1L3MBTL1SLC6A4
SCHEMBL10195154 0.72 GSK3A (0.64) KMT2AMAPTMEN1GAAHSD17B10
SCHEMBL10159100 0.72 MAPT (0.55) KMT2AMAPTMEN1GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3144299-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Cambria Pharmaceuticals, Inc. (US) 2017-03-22 EP disclosed
US-9499494-B2 Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis NORTHWESTERN UNIVERSITY (US) 2016-11-22 US disclosed
US-9499494-B2 Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis NORTHWESTERN UNIVERSITY (US) 2016-11-22 US disclosed
EP-2427438-B1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS CAMBRIA PHARMACEUTICALS INC (US) 2016-10-12 EP disclosed
US-20150203456-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST 2015-07-23 US disclosed
US-20150203456-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST 2015-07-23 US disclosed
US-20120046309-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS NORTHWESTERN UNIVERSITY (US) 2012-02-23 US disclosed
US-20120046309-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS NORTHWESTERN UNIVERSITY (US) 2012-02-23 US disclosed
WO-2010129665-A2 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS CAMBRIA PHARMACEUTICALS, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203456-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS NUDT1, TYMP, HPRT1 KMT2A 946/4885MAPT 6/4885MEN1 4617/4885
US-20120046309-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS NUDT1, TYMP, HPRT1 KMT2A 946/4885MAPT 6/4885MEN1 4617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.